Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Short-Term Debt issuances (2022)

NovaBay Pharmaceuticals (NBY) has disclosed Short-Term Debt issuances for 4 consecutive years, with -$105000.0 as the latest value for Q1 2022.

  • On a quarterly basis, Short-Term Debt issuances changed N/A to -$105000.0 in Q1 2022 year-over-year; TTM through Dec 2022 was -$105000.0, a N/A change, with the full-year FY2022 number at -$105000.0, down 200.0% from a year prior.
  • Short-Term Debt issuances was -$105000.0 for Q1 2022 at NovaBay Pharmaceuticals, down from $88000.0 in the prior quarter.
  • In the past five years, Short-Term Debt issuances ranged from a high of -$105000.0 in Q1 2022 to a low of -$105000.0 in Q1 2022.